Biofrontera Inc. (BFRI)

2.9400 +0.0700 (+2.44%) At close: 04:00PM EDT

Biofrontera Inc.

120 Presidential Way
Suite 330
Woburn, MA 01801
United States
781 245 1325
https://www.biofrontera.us.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 69

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Hermann Lubbert Ph.D.	Exec. Chairman & Pres	18.02k	N/A	1956
Ms. Erica L. Monaco CPA	CEO, CFO, COO, Treasurer & Sec.	402.12k	N/A	1985
Ms. Erica F. Gates CPA, M.B.A.	Sr. Director of Fin. & Principal Accounting Officer	N/A	N/A	N/A
Mr. Daniel Hakansson J.D.	Gen. Counsel & Head of Compliance	N/A	N/A	N/A
Mr. Mark Baldyga	Head of Sales & Marketing	N/A	N/A	N/A
Mr. Jeff Holm	Head of Professional Relations & Commercial Devel.	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Biofrontera Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.